OrbiMed

Ottimo Pharma specializes in developing innovative cancer therapies for solid tumors. Its primary focus is Jankistomig, a bi-functional antibody that targets both immune checkpoint inhibition and angiogenesis, two key pathways involved in cancer growth. By simultaneously addressing these pathways, Ottimo Pharma's approach offers healthcare professionals a dual-pronged strategy to potentially enhance treatment outcomes and reduce the burden of cancer on patients and the healthcare system.

Adela specializes in developing advanced technologies for the early detection of cancer and other serious health conditions through routine blood tests. The company's genome-wide methylome enrichment platform efficiently captures comprehensive data from the entire methylome, enabling the identification of highly informative methylated regions of the genome. This targeted approach facilitates the detection and classification of tumors using plasma cell-free DNA methylomes. Adela's innovations not only aid in cancer detection but also extend to prenatal diagnostics, cardiology, and the monitoring of immune responses, thereby enhancing overall healthcare outcomes.

Valneva is a biopharmaceutical company specializing in the development, manufacturing, and distribution of prophylactic vaccines for infectious diseases. Its portfolio comprises two commercially available vaccines (IXIARO/JESPECT for Japanese encephalitis and DUKORAL for traveler's diarrhea), along with vaccine candidates targeting Lyme disease, chikungunya virus, and COVID-19. Valneva operates through segments including Commercialized Vaccines, Covid-19 Vaccine, Vaccine Candidates, and Technologies & Services. The company aims to address significant unmet medical needs in infectious diseases by leveraging its expertise and capabilities to advance vaccine candidates through clinical trials and ultimately commercialize them.

LifeWell is a new entity formed through the merger of LifeCell’s diagnostics business and MFine.

Valneva is a biopharmaceutical company specializing in the development, manufacturing, and distribution of prophylactic vaccines for infectious diseases. Its portfolio comprises two commercially available vaccines (IXIARO/JESPECT for Japanese encephalitis and DUKORAL for traveler's diarrhea), along with vaccine candidates targeting Lyme disease, chikungunya virus, and COVID-19. Valneva operates through segments including Commercialized Vaccines, Covid-19 Vaccine, Vaccine Candidates, and Technologies & Services. The company aims to address significant unmet medical needs in infectious diseases by leveraging its expertise and capabilities to advance vaccine candidates through clinical trials and ultimately commercialize them.

MDClone Ltd. is a company that specializes in developing software for analyzing medical records while ensuring the privacy of patient data. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients, which allows researchers to study disease behavior, healthcare practices, and treatment outcomes without exposing actual patient information. The MDClone ADAMS Platform provides a self-service data analytics environment that facilitates exploration, discovery, and collaboration across healthcare systems, both nationally and internationally. This innovative approach addresses common barriers in healthcare by enabling users to organize and access data efficiently, thereby improving operations and enhancing patient outcomes. MDClone serves various clients in the healthcare sector, including major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

Nucleix Ltd. is a company that develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Founded in 2008 and headquartered in Rehovot, Israel, with an additional office in San Diego, California, Nucleix focuses on identifying subtle changes in DNA methylation patterns to enhance cancer detection. The company's key products include Bladder EpiCheck, a urine test designed for monitoring bladder cancer, and Lung EpiCheck, a blood test aimed at the early detection of lung cancer. By leveraging proprietary biomarker assays, Nucleix enables healthcare providers to improve treatment outcomes through more accurate cancer screening and monitoring. The company has established distribution partnerships in several countries, including Israel, the Netherlands, Turkey, Russia, Italy, and Denmark.

PierianDx, Inc. is a biotechnology company that specializes in developing a cloud-based genomic software solution aimed at managing, analyzing, and interpreting complex genomic tests for clinical laboratories in the United States. Founded in 2014 and headquartered in Saint Louis, Missouri, PierianDx offers its Clinical Genomicist Workstation, which streamlines the workflow for patient cases, encompassing aspects from case accessioning to final report generation and integration with electronic health records. The company's software employs artificial intelligence to enhance the efficiency of genomic sequencing processes, thereby empowering healthcare providers to better diagnose and treat patients with cancer and other complex diseases. PierianDx also provides consulting and technical services, and collaborates strategically with organizations like RTI International. Through its accredited laboratory and extensive knowledgebase, the company supports health systems, children's hospitals, comprehensive cancer centers, and commercial laboratories in delivering integrated genomic care.

Scout Bio, Inc. is a biotechnology company focused on developing innovative therapies for chronic health conditions in pets, utilizing veterinary biotechnology and gene therapy. Founded in 2016 and based in Philadelphia, Pennsylvania, the company specializes in creating one-time treatments to address significant issues such as anemia linked to chronic kidney disease in cats. Scout Bio employs Adeno-associated viral vector technology to design and deliver protein and monoclonal antibody therapeutics through single intra-muscular injections. The company's mission is to apply advancements from human medicine to improve veterinary care and enhance the quality of life for pets.

PharmEasy is a health tech startup founded in 2015 by Dharmil Sheth, Mikhil Innani, and Dhaval Shah as a subsidiary of Ascent Health. The company operates an online platform that offers a range of healthcare services, including teleconsultation, medicine deliveries, and diagnostic test sample collections. By digitizing the pharmaceutical supply chain, PharmEasy connects patients with local pharmacies and diagnostic centers, facilitating access to essential medicines and healthcare products. This approach aims to make healthcare services more available, affordable, and accessible to patients.

Humacyte, Inc. is a medical research and development company based in Morrisville, North Carolina, focused on creating and commercializing human tissue-based products for regenerative medicine and vascular surgery. The company specializes in designing acellular extracellular matrices, which are crafted in vitro from banked vascular smooth muscle cells and decellularized to prevent rejection. These products serve as tissue-engineered grafts for patients requiring vascular repair or replacement. Humacyte's innovative approach aims to provide universally implantable bioengineered human tissues and organs, addressing various diseases, injuries, and chronic conditions while enhancing patient care and transforming medical practices. Founded in 2004, the company is committed to advancing solutions for vascular diseases and the replacement of anatomical conduits.

Rimag is a Shenzhen-based company specializing in medical imaging services. Founded in 2014, it operates medical imaging centers that provide examination and diagnostic services, including MRI, CT, PET, X-ray, ultrasound, and mammography. In addition to its imaging center operations, Rimag is involved in the development of relevant cloud technology and the training of professionals in the field. The company generates revenue through its comprehensive range of services, including Imaging Center Services, Imaging Solution Services, and Rimag Cloud Services.

Miaoshou Doctor is a healthcare service platform established in 2015 by Tao He and Daoliang Han, headquartered in Beijing. The company focuses on facilitating communication between patients and healthcare professionals, enabling effective management of post-diagnosis outcomes. Its platform empowers doctors to actively monitor their patients' health through ongoing counseling and prescription support, enhancing the overall patient care experience. By streamlining interactions and follow-ups, Miaoshou Doctor aims to improve health outcomes and foster better relationships between patients and their healthcare providers.

Adela specializes in developing advanced technologies for the early detection of cancer and other serious health conditions through routine blood tests. The company's genome-wide methylome enrichment platform efficiently captures comprehensive data from the entire methylome, enabling the identification of highly informative methylated regions of the genome. This targeted approach facilitates the detection and classification of tumors using plasma cell-free DNA methylomes. Adela's innovations not only aid in cancer detection but also extend to prenatal diagnostics, cardiology, and the monitoring of immune responses, thereby enhancing overall healthcare outcomes.

Nautilus Biotechnology is a development-stage life sciences company focused on advancing proteomics, the study of proteins and their functions, to enhance therapeutic development and medical diagnostics. The company has created a platform technology that aims to quantify and unravel the complexities of the human proteome. Its flagship product, the Proteomic Analysis System, is a prototype single-molecule instrument designed to facilitate these efforts. The team at Nautilus comprises experts from various disciplines, including protein chemistry, molecular biology, and data science, enabling a multifaceted approach to overcoming challenges in the field. By harnessing this diverse expertise, Nautilus aims to revolutionize drug development and improve healthcare management through personalized and predictive medicine.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, focused on developing point-of-care diagnostic solutions for infectious diseases. Established in 2005, the company offers the binx io system, a FDA-cleared and CLIA-waived platform that detects sexually transmitted infections, including chlamydia and gonorrhea, delivering results comparable to central lab performance within approximately thirty minutes. Additionally, Binx Health provides the Callisto system, which meets various throughput requirements for testing in decentralized and near-patient settings. The company's innovative approach aims to enhance access to healthcare by overcoming traditional barriers and improving patient experiences through rapid polymerase chain reaction (PCR)-based testing and a comprehensive digital program that includes counseling and follow-up care. Binx Health has also formed a strategic partnership with Sherlock Biosciences to further advance its capabilities in diagnostics.

Nucleix Ltd. is a company that develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Founded in 2008 and headquartered in Rehovot, Israel, with an additional office in San Diego, California, Nucleix focuses on identifying subtle changes in DNA methylation patterns to enhance cancer detection. The company's key products include Bladder EpiCheck, a urine test designed for monitoring bladder cancer, and Lung EpiCheck, a blood test aimed at the early detection of lung cancer. By leveraging proprietary biomarker assays, Nucleix enables healthcare providers to improve treatment outcomes through more accurate cancer screening and monitoring. The company has established distribution partnerships in several countries, including Israel, the Netherlands, Turkey, Russia, Italy, and Denmark.

EDDA Technology specializes in computer-assisted solutions for patient care management, focusing on enhancing the efficiency and effectiveness of imaging-guided cancer treatment. The company has developed the IQQA platform, which provides innovative imaging solutions that improve workflow and patient care in various surgical contexts, including open, minimally invasive, and robotic surgeries. The platform promotes a patient-specific and disease-targeted approach, facilitating a multidisciplinary strategy for cancer treatment. It supports the entire surgical process, including pre-surgical planning and simulation, intra-operative guidance and monitoring, post-operative follow-up, and training. By enabling advanced clinical applications such as automated volumetric organ segmentation and virtual treatment simulation, EDDA Technology aims to improve early disease detection and diagnosis, ultimately enhancing patient outcomes.

Crossover Health, established in 2010, specializes in providing comprehensive workplace healthcare services for employers and their employees. Headquartered in Aliso Viejo, California, with health centers across the United States, the company offers a wide range of services including primary care, urgent care, chronic disease management, health coaching, physical therapy, and more. Crossover Health aims to deliver exceptional member experiences and advanced health management services, ultimately promoting a healthy and motivated workforce for its clients.

Miaoshou Doctor is a healthcare service platform established in 2015 by Tao He and Daoliang Han, headquartered in Beijing. The company focuses on facilitating communication between patients and healthcare professionals, enabling effective management of post-diagnosis outcomes. Its platform empowers doctors to actively monitor their patients' health through ongoing counseling and prescription support, enhancing the overall patient care experience. By streamlining interactions and follow-ups, Miaoshou Doctor aims to improve health outcomes and foster better relationships between patients and their healthcare providers.

CoreMap, Inc. is dedicated to enhancing patient outcomes through advanced diagnostic technology tailored for electrophysiologists treating atrial fibrillation. Founded in 2016 and based in Winooski, Vermont, the company has developed a micro-electrode solution that allows for sequential mapping of tissue properties. This innovative technology addresses critical challenges in atrial fibrillation treatment, specifically poor spatial resolution and inadequate sample density. CoreMap's ultra-high resolution electrodes provide detailed insights into cardiac activation, even in the presence of fibrillation, thereby enabling medical practitioners to offer more effective treatment options for patients.

MobileODT Ltd develops optical diagnostic devices and software services aimed at early cancer detection. The company offers the EVA COLPO, a portable and FDA-cleared colposcope that connects to the internet, making it easy for healthcare providers to conduct examinations. The EVA SANE system allows for the secure management of patient data, including photos and notes, on a HIPAA-compliant server. Additionally, the EVA WELL tool enhances gynecologic exams through digital visualization. MobileODT also provides a mobile application for remote image capture and patient information tracking, alongside a cloud-based portal for collaboration and reporting. Other products include Eviscope, designed for documenting violence and abuse, EviDx for case documentation, and EviCenter for managing patient data. Founded in 2012 and headquartered in Tel Aviv, Israel, with an office in New York, MobileODT has established a strong presence in markets such as the U.S., Africa, and India, having conducted over 40,000 procedures across 29 countries.

Perfuse Therapeutics is a biotechnology company dedicated to developing innovative therapies for eye diseases, with a primary focus on glaucoma. The company aims to improve retinal perfusion, which is critical in addressing various retinal conditions. By utilizing a novel mechanism to enhance blood flow to the retina, Perfuse Therapeutics seeks to provide treatment options that can slow the progression of glaucoma, as well as other retinal diseases such as non-proliferative diabetic retinopathy and retinal vein occlusion. Through its research and development efforts, the company is working to advance the standard of care for patients suffering from these conditions.

New Horizon Health is a biotechnology company based in Hangzhou, China, with an additional office in Beijing, specializing in the development of innovative technologies for early cancer detection and screening. Founded in 2015, the company primarily focuses on gastrointestinal cancers, offering products such as the ColoClear and Pupu Tube, which utilize fecal gene analysis (FIT-DNA) technology for colorectal cancer screening. These products enable users to conduct in-home tests, allowing for the early detection of colon cancer and precancerous lesions that may not be identified through traditional blood tests. New Horizon Health aims to reduce cancer morbidity and mortality rates by promoting accessible and efficient health services, leveraging big data and artificial intelligence in its screening technologies. The company's commitment to early cancer screening reflects its mission to enhance public health by facilitating widespread access to vital diagnostic tools.

TransMedics Group, Inc., established in 1998 and based in Andover, Massachusetts, is a commercial-stage medical technology company specializing in transforming organ transplant therapy for end-stage organ failure patients worldwide. The company's core product, the Organ Care System (OCS), is a portable, innovative technology that maintains donor organs outside the body in a near-physiologic state, replicating human-like conditions. This system includes OCS LUNG and OCS Heart, designed to preserve and optimize lungs and hearts respectively during transport, allowing for better assessment and improvement of organ condition. TransMedics also offers clinical services to enhance transplant volume, improve outcomes, and reduce learning curves for healthcare providers.

MDClone Ltd. is a company that specializes in developing software for analyzing medical records while ensuring the privacy of patient data. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients, which allows researchers to study disease behavior, healthcare practices, and treatment outcomes without exposing actual patient information. The MDClone ADAMS Platform provides a self-service data analytics environment that facilitates exploration, discovery, and collaboration across healthcare systems, both nationally and internationally. This innovative approach addresses common barriers in healthcare by enabling users to organize and access data efficiently, thereby improving operations and enhancing patient outcomes. MDClone serves various clients in the healthcare sector, including major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

Jinxin Fertility Group Limited is a prominent provider of assisted reproductive services (ARS) with operations in China and the United States. Established in 2003 and headquartered in Chengdu, China, the company offers various treatment options, including artificial insemination with either the patient's or donor's sperm and in vitro fertilization (IVF) techniques, such as conventional IVF and intracytoplasmic sperm injection (ICSI). In addition to reproductive services, Jinxin Fertility provides complementary offerings like nutrition guidance, Chinese medicine treatment, and psychological counseling to enhance patient support. The company operates several subsidiaries, including Chengdu Xinan and Shenzhen Zhongshan, as well as HRC in the United States, thereby expanding its network and service capabilities. Jinxin Fertility's commitment to high-quality care and innovative reproductive solutions has positioned it as a leader in the field.

Asian Institute of Medical Sciences is a 425-bed super specialty hospital located in Delhi NCR, India, dedicated to providing accessible and affordable healthcare services. The hospital is accredited by NABH and NABL and aims to meet the healthcare needs of the modern era through its comprehensive multi-specialty tertiary care facilities. It operates 14 centers of excellence, which include specialized departments such as the Asian Cancer Centre, Asian Centre for Bone Marrow Transplant, Asian Heart Centre, and Asian Centre for Neurology and Neurosurgery. In addition to its preventive, diagnostic, therapeutic, rehabilitative, and palliative care services, the hospital also offers advanced imaging, laboratory, and radiology services, ensuring a holistic approach to patient care.

MDClone Ltd. is a company that specializes in developing software for analyzing medical records while ensuring the privacy of patient data. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients, which allows researchers to study disease behavior, healthcare practices, and treatment outcomes without exposing actual patient information. The MDClone ADAMS Platform provides a self-service data analytics environment that facilitates exploration, discovery, and collaboration across healthcare systems, both nationally and internationally. This innovative approach addresses common barriers in healthcare by enabling users to organize and access data efficiently, thereby improving operations and enhancing patient outcomes. MDClone serves various clients in the healthcare sector, including major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

MobileODT Ltd develops optical diagnostic devices and software services aimed at early cancer detection. The company offers the EVA COLPO, a portable and FDA-cleared colposcope that connects to the internet, making it easy for healthcare providers to conduct examinations. The EVA SANE system allows for the secure management of patient data, including photos and notes, on a HIPAA-compliant server. Additionally, the EVA WELL tool enhances gynecologic exams through digital visualization. MobileODT also provides a mobile application for remote image capture and patient information tracking, alongside a cloud-based portal for collaboration and reporting. Other products include Eviscope, designed for documenting violence and abuse, EviDx for case documentation, and EviCenter for managing patient data. Founded in 2012 and headquartered in Tel Aviv, Israel, with an office in New York, MobileODT has established a strong presence in markets such as the U.S., Africa, and India, having conducted over 40,000 procedures across 29 countries.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Suraksha Diagnostics, established in 1992 in Kolkata, is a prominent provider of comprehensive pathology and radiology services. As one of the earliest diagnostic centers in the region, it has gained a reputation for accuracy and high-quality service. The company expanded rapidly, opening a second facility in Siliguri within three years, which has since become the largest diagnostic center in North Bengal, catering to patients from the surrounding areas and neighboring states. Suraksha Diagnostics continues to grow its footprint across Bengal, Bihar, and the Delhi NCR, offering specialized diagnostic tests in areas such as imaging, cardiology, neurology, and gastroenterology. The organization aims to enhance industry standards through a robust network of laboratory and imaging services, along with tailored offerings for its clientele.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Ornim, Inc. is a biomedical technology company based in Santa Clarita, California, with a research and development subsidiary in Israel. Founded in 2004, Ornim specializes in the development and distribution of non-invasive medical monitoring tools that measure blood flow and oxygen saturation in patients. Its primary products, CerOx and c-FLOW, utilize patented UTLight technology to provide real-time, continuous monitoring of cerebral blood flow and tissue oxygenation. CerOx is notable for being the only device on the market that simultaneously measures both blood flow and oxygen saturation, while c-FLOW focuses solely on cerebral blood flow measurement. These devices are designed to assist physicians in making informed clinical decisions, ultimately improving patient outcomes and reducing healthcare costs. Ornim's technology addresses the limitations of existing monitoring methods, and the company holds numerous patents to protect its innovations.

MDClone Ltd. is a company that specializes in developing software for analyzing medical records while ensuring the privacy of patient data. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients, which allows researchers to study disease behavior, healthcare practices, and treatment outcomes without exposing actual patient information. The MDClone ADAMS Platform provides a self-service data analytics environment that facilitates exploration, discovery, and collaboration across healthcare systems, both nationally and internationally. This innovative approach addresses common barriers in healthcare by enabling users to organize and access data efficiently, thereby improving operations and enhancing patient outcomes. MDClone serves various clients in the healthcare sector, including major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

Response Biomedical Corp. specializes in the research, development, and commercialization of rapid diagnostic technologies for various markets, including medical central-lab testing, point of care (POC) testing, and environmental testing. The company operates the RAMP® Platform, which utilizes portable fluorescence immunoassay technology to deliver laboratory-quality results quickly. This platform supports a range of applications, such as early detection of heart conditions, respiratory infections, and environmental hazards. Response Biomedical's tests are designed for use in acute care settings and can be performed using portable devices or compact analyzers. Their products are distributed globally, reaching markets in the United States, Asia, Europe, and beyond. Founded in 1980 and headquartered in Vancouver, Canada, Response Biomedical is committed to providing efficient diagnostic solutions for improved patient management and safety.

Nucleix Ltd. is a company that develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Founded in 2008 and headquartered in Rehovot, Israel, with an additional office in San Diego, California, Nucleix focuses on identifying subtle changes in DNA methylation patterns to enhance cancer detection. The company's key products include Bladder EpiCheck, a urine test designed for monitoring bladder cancer, and Lung EpiCheck, a blood test aimed at the early detection of lung cancer. By leveraging proprietary biomarker assays, Nucleix enables healthcare providers to improve treatment outcomes through more accurate cancer screening and monitoring. The company has established distribution partnerships in several countries, including Israel, the Netherlands, Turkey, Russia, Italy, and Denmark.

Eurolife Healthcare is a manufacturer and distributor of a diverse array of healthcare formulations tailored for various medical applications. The company specializes in producing generic pharmaceutical products, including intravenous infusions, ophthalmic solutions, sterilized water for injections, tablets, capsules, ointments, creams, and other formulations. Eurolife Healthcare emphasizes high-quality and sterile packaging to ensure that healthcare providers can effectively meet medical supply demands. Its product offerings extend to systems such as the eurohead infusion system, classic infusion therapy, and specialized solutions like Lifeflow and Germkill, designed to address specific therapeutic needs in the healthcare sector.

TigerConnect is a provider of clinical communication solutions tailored for the healthcare sector, enabling effective collaboration among doctors, nurses, patients, and care providers. Founded in 2010 and headquartered in Santa Monica, California, the company offers a platform that integrates real-time mobile messaging with a user-friendly interface, while prioritizing security and privacy. Trusted by over 4,000 healthcare organizations, TigerConnect processes more than 10 million messages daily and boasts a 99.99% uptime. Its innovative products and seamless integrations with essential hospital systems enhance workflow efficiency, ultimately accelerating productivity, reducing costs, and improving patient outcomes. The company's commitment to client success is evident through its dedicated support organization, which collaborates with clients to optimize communication workflows and maximize return on investment.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Sikka.ai provides a cloud-based platform designed to transform the retail healthcare market, focusing on non-physician practices such as dentistry, veterinary care, optometry, chiropractic, orthodontics, and oral surgery. The company's award-winning single API platform leverages artificial intelligence and predictive analytics to connect with 96% of the retail healthcare market. With over 35,000 practice installations and 120 million patients on its platform, Sikka.ai facilitates the integration of various practice management and financial systems, enabling healthcare providers to optimize their operations. The platform features 50 applications developed by various suppliers, including Fortune 500 companies, along with four proprietary applications. Sikka.ai aims to create a real-time global platform that empowers patients, providers, and suppliers, addressing a market with an annual services expenditure exceeding $260 billion. The company’s innovative approach was recognized with the Best Health API Award in 2019.

Natera, Inc. is a diagnostic and research company specializing in genetic testing services, particularly in the areas of preconception and prenatal diagnostics. Founded in 2003 and headquartered in San Carlos, California, Natera offers a range of products including the Panorama non-invasive prenatal test, which screens for chromosomal abnormalities in fetuses, and Vistara, a test for single-gene mutations. Additionally, the company provides Horizon carrier screening to assess carrier status for various genetic diseases, and Spectrum, which analyzes genetic conditions during in vitro fertilization. Natera's Anora product analyzes fetal chromosomes to understand miscarriage causes, while its non-invasive paternity tests determine parentage through fetal DNA analysis. The company's Signatera technology focuses on circulating tumor DNA to monitor cancer recurrence. Natera distributes its products through a direct sales force and a network of approximately 100 laboratory and distribution partners, both domestically and internationally. The company collaborates with BGI Genomics to develop genetic testing assays and has partnered with Foundation Medicine for personalized cancer monitoring assays.

Invitae is a genetic information company focused on integrating genetic insights into everyday medical practice to enhance healthcare quality for a large population. The company specializes in genetic diagnostics for hereditary disorders, offering a comprehensive service that consolidates multiple genetic tests into a single platform. Invitae's offerings include assessments for genes linked to hereditary cancer, neurological disorders, cardiovascular conditions, pediatric issues, metabolic disorders, and other hereditary ailments. By providing high-quality testing with quicker turnaround times and competitive pricing, Invitae aims to make genetic testing more accessible and effective for patients and healthcare providers alike.

Rapid Pathogen Screening, Inc. is a biotechnology company based in Sarasota, Florida, founded in 2004. It specializes in developing, manufacturing, and marketing rapid point-of-care diagnostic tests aimed at identifying infectious diseases, inflammatory conditions, and threats from bio-terrorism and chemical nerve agents. The company's product portfolio includes AdenoPlus, which detects various serotypes of adenoviral conjunctivitis, and InflammaDry, a test for dry eye, both of which are available to healthcare professionals in the United States and internationally. Rapid Pathogen Screening utilizes a patented technology platform that ensures high sensitivity and specificity in its tests, enabling healthcare providers to conduct accurate diagnoses with minimal training and equipment. The company distributes its products through various channels, underscoring its commitment to improving patient health and reducing healthcare costs associated with disease management.

Ornim, Inc. is a biomedical technology company based in Santa Clarita, California, with a research and development subsidiary in Israel. Founded in 2004, Ornim specializes in the development and distribution of non-invasive medical monitoring tools that measure blood flow and oxygen saturation in patients. Its primary products, CerOx and c-FLOW, utilize patented UTLight technology to provide real-time, continuous monitoring of cerebral blood flow and tissue oxygenation. CerOx is notable for being the only device on the market that simultaneously measures both blood flow and oxygen saturation, while c-FLOW focuses solely on cerebral blood flow measurement. These devices are designed to assist physicians in making informed clinical decisions, ultimately improving patient outcomes and reducing healthcare costs. Ornim's technology addresses the limitations of existing monitoring methods, and the company holds numerous patents to protect its innovations.

TigerConnect is a provider of clinical communication solutions tailored for the healthcare sector, enabling effective collaboration among doctors, nurses, patients, and care providers. Founded in 2010 and headquartered in Santa Monica, California, the company offers a platform that integrates real-time mobile messaging with a user-friendly interface, while prioritizing security and privacy. Trusted by over 4,000 healthcare organizations, TigerConnect processes more than 10 million messages daily and boasts a 99.99% uptime. Its innovative products and seamless integrations with essential hospital systems enhance workflow efficiency, ultimately accelerating productivity, reducing costs, and improving patient outcomes. The company's commitment to client success is evident through its dedicated support organization, which collaborates with clients to optimize communication workflows and maximize return on investment.

RedHill Biopharma Ltd. is a specialty biopharmaceutical company headquartered in Tel Aviv, Israel, with a primary focus on gastrointestinal and infectious diseases. The company develops and promotes several gastrointestinal drugs, including Movantik for opioid-induced constipation, Talicia for treating Helicobacter pylori infection, and Aemcolo for travelers' diarrhea. RedHill's late-stage clinical development programs include RHB-204, aimed at treating pulmonary nontuberculous mycobacteria infections; RHB-104 for Crohn's disease; and RHB-102 (Bekinda), which has shown promise in Phase 3 studies for acute gastroenteritis and gastritis. Additionally, the company is advancing RHB-107, a serine protease inhibitor for cancer and inflammatory gastrointestinal diseases, and opaganib, which is being investigated for various conditions, including COVID-19. Founded in 2009, RedHill Biopharma is committed to innovation in the management of gastrointestinal and infectious diseases.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Practice Fusion, Inc. is a cloud-based electronic health records (EHR) company based in San Francisco, California, founded in 2005. The company specializes in providing a comprehensive practice management software platform that facilitates various healthcare functions, including charting, scheduling, billing, e-prescribing, lab integrations, and secure messaging. By connecting doctors, patients, and data, Practice Fusion aims to enhance healthcare delivery and improve patient outcomes. Its platform serves a diverse range of users, including independent medical practices, large medical groups, and community clinics, as well as life science partners. Additionally, Practice Fusion Insight offers a healthcare database to support medical professionals in their practice. As of February 2018, Practice Fusion operates as a subsidiary of Allscripts Healthcare Solutions, Inc.

Amoy Diagnostics is a research and development based diagnostic company focusing on molecular diagnostics for oncology precision medicine. AmoyDx has a portfolio of molecular diagnostic assays. Based on multiple technology platforms including PCR, NGS, FISH and IHC, AmoyDx's core product categories include single gene testing kits, multi-gene testing panels, NGS panels, and NGS analytical systems.

Singulex, Inc. is an immunodiagnostics and biotechnology company that specializes in single molecule counting (SMC) technology for clinical diagnostics and scientific research. The company has developed the Sgx Clarity System, an in vitro diagnostics platform capable of detecting low abundance biomarkers at levels down to femtograms/mL. This system assists clinicians in managing cardiovascular health, while also providing heart disease monitoring services and personalized wellness programs for patients. Singulex's offerings include ultra-sensitive immunoassay solutions and laboratory testing services that facilitate both reactive and proactive health management, as well as support the discovery of new therapeutics. The company serves a diverse clientele, including pharmaceutical research laboratories, clinical research organizations, and academic institutions globally. Additionally, Singulex is involved in pilot studies to validate its Erenna BioAssay System, which enhances molecular detection capabilities. Founded in 1997 and based in Alameda, California, Singulex has an additional office in Basel, Switzerland, and was previously known as BioProfile Corporation until its name change in 2003.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Natera, Inc. is a diagnostic and research company specializing in genetic testing services, particularly in the areas of preconception and prenatal diagnostics. Founded in 2003 and headquartered in San Carlos, California, Natera offers a range of products including the Panorama non-invasive prenatal test, which screens for chromosomal abnormalities in fetuses, and Vistara, a test for single-gene mutations. Additionally, the company provides Horizon carrier screening to assess carrier status for various genetic diseases, and Spectrum, which analyzes genetic conditions during in vitro fertilization. Natera's Anora product analyzes fetal chromosomes to understand miscarriage causes, while its non-invasive paternity tests determine parentage through fetal DNA analysis. The company's Signatera technology focuses on circulating tumor DNA to monitor cancer recurrence. Natera distributes its products through a direct sales force and a network of approximately 100 laboratory and distribution partners, both domestically and internationally. The company collaborates with BGI Genomics to develop genetic testing assays and has partnered with Foundation Medicine for personalized cancer monitoring assays.

Treato Ltd. operates a health information platform that aggregates and analyzes patient experiences sourced from the Internet, particularly from social media sites and forums. The platform provides valuable insights for patients, healthcare professionals, pharmaceutical companies, and other healthcare organizations. By employing advanced Natural Language Processing, Treato extracts relevant information from the vast amount of patient-written health experiences, creating a comprehensive understanding of public sentiment regarding medications and health conditions. Treato also offers Treato Pharma, a specialized service that delivers real-time analytics and insights to pharmaceutical marketers, helping them interpret patient opinions, understand competitive dynamics, and enhance patient engagement. Founded in 2008 and based in Yehud, Israel, Treato serves as a critical resource for both consumers and the healthcare industry, with its advertising-free consumer site attracting hundreds of thousands of users weekly.

CardiAQ Valve Technologies is a privately held company specializing in advanced solutions for heart valve replacement, with a primary focus on transcatheter mitral valve implantation (TMVI). The company has developed a system that allows physicians to implant a mitral valve within a beating heart, thereby eliminating the need for open-heart surgery. This innovative approach aims to enhance patient outcomes and simplify the procedure for both patients and healthcare providers.

Ornim, Inc. is a biomedical technology company based in Santa Clarita, California, with a research and development subsidiary in Israel. Founded in 2004, Ornim specializes in the development and distribution of non-invasive medical monitoring tools that measure blood flow and oxygen saturation in patients. Its primary products, CerOx and c-FLOW, utilize patented UTLight technology to provide real-time, continuous monitoring of cerebral blood flow and tissue oxygenation. CerOx is notable for being the only device on the market that simultaneously measures both blood flow and oxygen saturation, while c-FLOW focuses solely on cerebral blood flow measurement. These devices are designed to assist physicians in making informed clinical decisions, ultimately improving patient outcomes and reducing healthcare costs. Ornim's technology addresses the limitations of existing monitoring methods, and the company holds numerous patents to protect its innovations.

Good Start Genetics, Inc. is a molecular diagnostics company based in Cambridge, Massachusetts, focused on genetic screening for inherited diseases. Founded in 2007, the company aims to transform reproductive medicine by providing physicians and patients with actionable insights into inherited genetic disorders. Good Start Genetics offers a range of services, including EmbryVu, a preimplantation genetic screening test designed to enhance in vitro fertilization outcomes by identifying suitable embryos for implantation. The company employs advanced next-generation DNA sequencing technology, along with other established genetic screening methods, to deliver high carrier detection rates. Additionally, through its GoodStart Select program, it provides a comprehensive menu of genetic carrier screening tests for both known and novel mutations, all supported by a commitment to customer care and genetic counseling. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

Singulex, Inc. is an immunodiagnostics and biotechnology company that specializes in single molecule counting (SMC) technology for clinical diagnostics and scientific research. The company has developed the Sgx Clarity System, an in vitro diagnostics platform capable of detecting low abundance biomarkers at levels down to femtograms/mL. This system assists clinicians in managing cardiovascular health, while also providing heart disease monitoring services and personalized wellness programs for patients. Singulex's offerings include ultra-sensitive immunoassay solutions and laboratory testing services that facilitate both reactive and proactive health management, as well as support the discovery of new therapeutics. The company serves a diverse clientele, including pharmaceutical research laboratories, clinical research organizations, and academic institutions globally. Additionally, Singulex is involved in pilot studies to validate its Erenna BioAssay System, which enhances molecular detection capabilities. Founded in 1997 and based in Alameda, California, Singulex has an additional office in Basel, Switzerland, and was previously known as BioProfile Corporation until its name change in 2003.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

The Kerala Institute of Medical Sciences is a multi-specialty tertiary care hospital located in Thiruvananthapuram, India, dedicated to providing high-quality medical services through a combination of specialist expertise and advanced technology. Founded in 2002, the institution focuses on making healthcare accessible and affordable for the community. It encompasses a range of services from primary to quaternary care, including health check programs and emergency services. In addition to its hospital operations, the Kerala Institute of Medical Sciences is involved in medical education, offering specialized courses for nurses and postgraduate programs for doctors, including 20 DNB programmes and various fellowship courses. The organization also features a College of Nursing and an Institute of Skill Development and Paramedical Institute, reflecting its commitment to quality patient care, research, and education.

Roka Bioscience specializes in the development of rapid and accurate molecular assays and instrument systems aimed at the food safety industry. The company's latest innovation, the Atlas System, introduces advanced molecular rapid pathogen testing, which enhances laboratory efficiency through automation and user-friendly design. By focusing on innovative testing solutions, Roka Bioscience aims to assist food manufacturers in minimizing risks, safeguarding their brands, and addressing the growing demands for testing in the sector.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Roka Bioscience specializes in the development of rapid and accurate molecular assays and instrument systems aimed at the food safety industry. The company's latest innovation, the Atlas System, introduces advanced molecular rapid pathogen testing, which enhances laboratory efficiency through automation and user-friendly design. By focusing on innovative testing solutions, Roka Bioscience aims to assist food manufacturers in minimizing risks, safeguarding their brands, and addressing the growing demands for testing in the sector.

Good Start Genetics, Inc. is a molecular diagnostics company based in Cambridge, Massachusetts, focused on genetic screening for inherited diseases. Founded in 2007, the company aims to transform reproductive medicine by providing physicians and patients with actionable insights into inherited genetic disorders. Good Start Genetics offers a range of services, including EmbryVu, a preimplantation genetic screening test designed to enhance in vitro fertilization outcomes by identifying suitable embryos for implantation. The company employs advanced next-generation DNA sequencing technology, along with other established genetic screening methods, to deliver high carrier detection rates. Additionally, through its GoodStart Select program, it provides a comprehensive menu of genetic carrier screening tests for both known and novel mutations, all supported by a commitment to customer care and genetic counseling. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Singulex, Inc. is an immunodiagnostics and biotechnology company that specializes in single molecule counting (SMC) technology for clinical diagnostics and scientific research. The company has developed the Sgx Clarity System, an in vitro diagnostics platform capable of detecting low abundance biomarkers at levels down to femtograms/mL. This system assists clinicians in managing cardiovascular health, while also providing heart disease monitoring services and personalized wellness programs for patients. Singulex's offerings include ultra-sensitive immunoassay solutions and laboratory testing services that facilitate both reactive and proactive health management, as well as support the discovery of new therapeutics. The company serves a diverse clientele, including pharmaceutical research laboratories, clinical research organizations, and academic institutions globally. Additionally, Singulex is involved in pilot studies to validate its Erenna BioAssay System, which enhances molecular detection capabilities. Founded in 1997 and based in Alameda, California, Singulex has an additional office in Basel, Switzerland, and was previously known as BioProfile Corporation until its name change in 2003.

Innovative Spinal Technologies is a spine technology company based in Mansfield, Massachusetts, that specializes in developing motion preservation and minimally invasive treatments for spinal disorders. Founded in 2002, the company offers a range of products designed to enhance surgical outcomes in spinal procedures. Its AXIENT Dynamic Fixation system is a pedicle screw-based motion system, while the PARAMOUNT product line includes several systems tailored for lumbar fusion procedures. This includes the PARAMOUNT Lumbar Fusion System, which can be used in minimally invasive, mini-open, or open surgical techniques, as well as the PARAMOUNT MIS and Open Pedicle Screw Systems, designed for single and multi-level procedures. Additionally, the PARAMOUNT VBR is engineered for a minimally invasive transforaminal approach.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Gelesis, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing innovative therapies for gastrointestinal-related chronic diseases, particularly obesity and its associated conditions. The company utilizes a mechanobiology technology platform to create its lead product, Gelesis100, an orally administered smart pill that contains hydrogel particles. This product is designed to expand in the stomach, promoting a feeling of fullness and aiding in weight management. Gelesis also offers PLENITY, an FDA-cleared product that assists individuals with weight management. In addition to these offerings, Gelesis has a pipeline of potential therapeutics targeting conditions such as Type 2 diabetes, non-alcoholic fatty liver disease, and chronic idiopathic constipation. Established in 2006, Gelesis aims to provide safe and effective solutions for patients dealing with obesity and related health issues.

Singulex, Inc. is an immunodiagnostics and biotechnology company that specializes in single molecule counting (SMC) technology for clinical diagnostics and scientific research. The company has developed the Sgx Clarity System, an in vitro diagnostics platform capable of detecting low abundance biomarkers at levels down to femtograms/mL. This system assists clinicians in managing cardiovascular health, while also providing heart disease monitoring services and personalized wellness programs for patients. Singulex's offerings include ultra-sensitive immunoassay solutions and laboratory testing services that facilitate both reactive and proactive health management, as well as support the discovery of new therapeutics. The company serves a diverse clientele, including pharmaceutical research laboratories, clinical research organizations, and academic institutions globally. Additionally, Singulex is involved in pilot studies to validate its Erenna BioAssay System, which enhances molecular detection capabilities. Founded in 1997 and based in Alameda, California, Singulex has an additional office in Basel, Switzerland, and was previously known as BioProfile Corporation until its name change in 2003.

Amnis manufactures and supplies flow cytometry products and services. Their technology is used in research and clinical studies with biomedical and therapeutic applications, including investigating the role of the body’s immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients.

Innovative Spinal Technologies is a spine technology company based in Mansfield, Massachusetts, that specializes in developing motion preservation and minimally invasive treatments for spinal disorders. Founded in 2002, the company offers a range of products designed to enhance surgical outcomes in spinal procedures. Its AXIENT Dynamic Fixation system is a pedicle screw-based motion system, while the PARAMOUNT product line includes several systems tailored for lumbar fusion procedures. This includes the PARAMOUNT Lumbar Fusion System, which can be used in minimally invasive, mini-open, or open surgical techniques, as well as the PARAMOUNT MIS and Open Pedicle Screw Systems, designed for single and multi-level procedures. Additionally, the PARAMOUNT VBR is engineered for a minimally invasive transforaminal approach.

Amnis manufactures and supplies flow cytometry products and services. Their technology is used in research and clinical studies with biomedical and therapeutic applications, including investigating the role of the body’s immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients.